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Introduction {#s1}
============

Autism spectrum disorder (ASD) is defined according to deficits in social communication and presence of restricted behaviors. This neurodevelopmental condition currently affects about 1 in 68 U.S. children, and is approximately four times more common in males than females ([@c12]). The etiology of ASD remains largely unexplained; however, evidence supports the influence of both genetic and environmental factors acting in the prenatal period ([@c57]; [@c52]). We recently reported that prenatal exposure to certain polychlorinated biphenyl (PCBs) congeners was positively associated with odds of ASD ([@c47]). Like PCBs, polybrominated diphenyl ethers (PBDEs) and the chemical 2,2′,4,4′,5,5′-hexabromobiphenyl (BB-153), known as brominated flame retardants (BFRs), are another class of endocrine-disrupting chemicals (EDCs). Developmental exposure to BFRs, and EDCs in general, has emerged as a suspected risk factor for ASD ([@c38]; [@c33]; [@c48]) given known influences of hormone disruptions on brain development ([@c19]; [@c51]; [@c14]).

Although many BFRs have been phased out of use in the United States, levels of these chemicals are still detected in human blood samples due to their lipophilic nature and the continued existence of products such as furniture and plastics that contain them ([@c39]; [@c64], [@c63]). Developmental concerns arose following evidence in animal studies that BFRs at levels within the range of high exposure in humans in recent decades impact brain development and neurodevelopmental outcomes relevant to ASD ([@c23], [@c24]; [@c4]; [@c14]; [@c68]). Further, BFRs can transfer from maternal to fetal circulation in humans ([@c50]; [@c28]; [@c31]; [@c9]), have been associated with thyroid hormone in humans ([@c10], [@c11]; [@c71]) and markers of immune function in humans and animal studies ([@c2]; [@c46]), and could suggest potential pathways through which these chemicals may influence fetal neurodevelopment and ASD.

To our knowledge, no published studies to date have considered prenatal BFR levels in association with risk of ASD diagnoses specifically. However, gestational exposure in some human epidemiological studies has been shown to be associated with evidence of cognitive deficits, behavioral impairments, and attention problems ([@c37]; [@c20]; [@c17]; [@c8]; [@c36]; [@c15]; [@c60]). Only one study ([@c5]) has examined prenatal BFR levels in association with offspring autistic traits as measured by the Social Responsiveness Scale ([@c13]). This cohort study including 175 women reported evidence of positive, inverse, and null associations, depending on the congener assessed. Another investigation, a population-based case--control study including 100 children, did not find significant differences in current PBDE levels between children with ASD ($n = 51$) and those with typical development ($n = 23$) ([@c38]). However, measurements were conducted in childhood (mean age 3.7 y), after diagnosis, and thus may not represent the suspected developmentally relevant period of exposure during prenatal neurodevelopment ([@c58]; [@c55]; [@c57]).

In order to address these prior limitations and examine the potential role that prenatal exposure to BFRs plays in risk of ASD and in broader adverse neurodevelopment as defined by intellectual disability (ID), we used data from a large population-based case--control study in California. Given the suggested neurodevelopmental toxicity of BFRs, we hypothesized that higher levels of BFRs would be found in prenatal samples from mothers of children with ASD relative to mothers of control children without developmental delays, and that similar associations may be seen with ID. Given evidence for endocrine disruption activity and suggested sexually dimorphic effects of BFRs on neurobehavioral outcomes from animal work ([@c45]; [@c27]), we were also interested in exploring potential sex differences in risk of ASD and ID associated with prenatal BFR exposure.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

We used data from the Early Markers for Autism (EMA) study to address these questions. Details of EMA methods have been previously described in an earlier paper ([@c16]). Briefly, EMA is a population-based case--control study designed to identify biologic markers of autism using archived prenatal and newborn blood samples from California state-wide screening programs. The EMA study sample was drawn from the population of live-born children in three counties from Southern California (Orange, San Diego, and Imperial) in 2000--2003 who participated in the newborn screening program and whose mothers enrolled in the State's Prenatal Expanded Alpha-fetoprotein Screening Program (XAFP). Approximately 70% of women in California participate in prenatal screening, with samples stored from 7--10 diverse counties throughout the state. Newborn screening is mandatory in the state of California. Following selection (further described below), children were then linked to the prenatal specimen archive to identify those for whom prenatal specimens were available for inclusion in this study. Only mother--child pairs with live birth records linked to archived prenatal and newborn specimens were eligible for inclusion in EMA.

Diagnostic information for the study population was obtained from the California Department of Developmental Services (DDS), which provides services to individuals with substantial disabilities---including autism, intellectual disability, and other developmental disabilities. Further information on the DDS can be found on their website (<http://www.dds.ca.gov>). DDS data were linked to eligible live birth records for the study region to identify, based on DDS service codes: children with ASD or children with intellectual disability/developmental delay without autism (mental retardation of unknown etiology codes) (ID). GP controls were identified by randomly sampling from eligible birth certificates among strata of matching factors, excluding DDS clients. Individuals with Down syndrome were excluded from all study groups. At the time of data linkage with DDS in 2007 and 2009, children would have been between 4.5 and 9 y old; the majority of cases were between 4.5 and 7 y old when identified. GP controls were originally individually matched to ASD cases on sex, birth month, and birth year. (However, matched analyses were not used as primary analyses here in order to include those individuals originally identified as ID but whom, following clinician review, were found to meet ASD criteria; further described below in "*Diagnostic Verification*"). Study activities were approved by the institutional review board at Kaiser Permanente and by the California State Committee for the Protection of Human Subjects. Informed consent was not required for the EMA study, given that consent forms for the XAFP Screening program were distributed at the time of the blood collection, which stipulated that specimens and results from prenatal testing could be used for legitimate research purposes given appropriate IRB approval.

Diagnostic Verification {#s2.2}
-----------------------

Final case status of children with ASD and children with ID was determined by expert clinical review of diagnostic and clinical data abstracted from DDS records, using an approach based on national surveillance methodology ([@c74]). A final diagnostic classification of ASD was given if DSM-IV-TR criteria were met; in our analytic sample with BFR measurements, 413 children originally identified as ASD in DDS met these diagnostic criteria. Additionally, a total of 132 individuals originally identified as ID in DDS were reclassified as ASD following expert review of abstracted data. ASD cases were further qualified by presence/absence of intellectual disability (defined as for ID, but in the presence of ASD). Final classification of ID (intellectual disability without autism) was based on standardized test score results found in records (composite developmental/cognitive score $< 70$) in the absence of meeting ASD criteria.

Specimens and Measurements {#s2.3}
--------------------------

After screening was completed at the regional laboratory, newborn dried blood spots were routinely freezer archived, as has been done statewide since 1982, and maternal blood from Southern California was freezer archived as part of the California Department of Public Health's Project Baby's Breath. Maternal blood specimens were collected typically between 15 and 20 wk gestation (median: 16 wk, range 7--25 wk) in serum separator tubes by obstetrical care service providers and underwent XAFP testing within 7 d of collection at a central laboratory ($\text{median}\,\text{time} = 3\; d$). After 1--2 d of refrigeration, leftover serum and cell pellet specimens were stored at $- 20{^\circ}C$.

A total of 10 BFRs were measured in maternal serum samples (BB153, BDEs 17, 28, 47, 66, 85, 99, 100, 153, 154) at the Centers for Disease Control and Prevention. Determination of target analytes was performed by gas chromatography--isotope dilution high resolution mass spectrometry (GC-IDHRMS), employing a Double Focusing Sector (ThermoFinnigan DFS, Bremen, Germany) instrument ([@c42]). The measurements were performed in two batches March--April, 2012 ($N = 276$) and August--December, 2013 ($N = 1,080$), that is, up to 13 y after the collection of the serum samples between year 2000 and 2003. However, serum pools have been shown to be stable over multiple years, as is expected for persistent organic pollutants such as PBDEs ([@c64]; [@c70]). Hence, it can be assumed that no appreciable degradation of target analytes has occurred during the storage of the samples for close to a decade. Concentrations of the BFRs were reported as ng/g lipid weight (weight of serum lipids) after background subtraction (background refers to the contamination of blank samples in the same run as the unknowns). All concentration data were corrected for the average amount present in blank samples, and three blanks were included in every set of 30 samples. A variable amount of serum was available (median $1.2\; g$; range: $0.1–2.1\; g$); due to this, a variable limit of detection was applied proportional to the serum amount used, that is, detection limit (picograms) divided with the available serum amount (grams). In order to prevent biasing the data due to higher LODs at lower amount of available serum, we censored the data based on detection frequency of each individual congener. The method used to censor the data was to calculate the detection frequency for all analytes by categorized available serum amounts, that is, $< 0.2$; $0.2\,\text{to} < 0.4$; $0.4\,\text{to} < 0.6$; and $\geq 0.6\; g$. If the detection rate was less than 60% in a serum amount category with $< 0.6\; g$ of serum, the data was categorized as nonreportable in that category and any lower serum amount category. One hundred five samples in the full EMA study (7.7%) had serum amounts less than $0.6\; g$.

Statistical Analyses {#s2.4}
--------------------

These analyses included singleton births with final case status (see "*Diagnostic Verification*") and BFR measurements available. Individuals missing all biomarker measurements (due to insufficient sample; $n = 5$), and individuals censored due to laboratory error (failure of automation system; $n = 33$) were excluded, leaving a total of 1,144 individuals. This number includes 545 children with ASD (287 with intellectual disability, 221 without intellectual disability, and 37 for whom we did not have information available to make an intellectual disability classification), 181 children with ID but not autism, and 418 GP control children.

For each of the BFRs measured, the percentage of the study group with levels above the limit of detection (LOD) was calculated. We used a cutoff detection rate of at least 55% of the study population with values above the LOD for selection of congeners with sufficient number of study participants with detectable values for further analysis. Among those congeners meeting this detection rate, individual measurements $< \text{LOD}$ were replaced with the LOD divided by the square root of 2 ([@c3]; [@c63]), although alternative methods for imputing values below the LOD were also utilized (see "*Sensitivity Analyses*" below). In addition to examining the individual congeners, we created a variable for combined BFR exposure by summing the individual concentrations of congeners (BB153, BDE-28, 47, 99, 100, and 153) meeting our detection rate cutoff. Other sums explored included BDE congeners only (e.g., not including BB153), including only those congeners detected in at least 60% of the study population (which removed BDE-28 from the sum), and high (BDE-100 and -153) or low (BDE-28 and -47) brominated congener sums.

Descriptive statistics were compared between the ASD, ID, and GP groups, and correlation coefficients between congeners were calculated. Geometric mean concentrations were calculated, and were also compared by diagnostic group and potential confounders. Potential covariates (listed below) were selected on the basis of *a priori* associations with ASD and/or the BFRs, and obtained from birth certificates or XAFP screening program records.

In order to examine the relationship between concentrations of BFRs and ASD, examine potential dose response, and account for potential nonlinearity in the association, we examined the exposure--outcome relationship using *a*) quartiles of chemical concentrations or their sums (based on the control distribution), *b*) continuous concentrations, examining odds associated with a 10-fold BFR increase, and *c*) cubic splines to evaluate potential nonlinearity in the association and allow for flexibility in the dose--response relationship ([@c21]; [@c32]). For continuous analyses of 10-fold changes in exposure levels, continuous variables of BFR concentration (with values $< \text{LOD}$ replaced as described) were divided by 10, so that corresponding beta coefficients would have the interpretation of a 10-unit change in exposure level. Secondary analyses also examined alternate categorizations (e.g., deciles, 95th and 5th percentiles). As stated above, matching was broken in primary analyses in order to include all final ASD cases with biomarker measurements. Logistic regression was used to obtain crude (adjusted only for matching factors) and multivariable adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between the categorized (quartiles) congeners and ASD in comparison to GP controls. All final models included (variables obtained from birth records unless noted) the study matching factors (child sex, birth month, and birth year---the latter modeled as ordinal variables), maternal age (continuous), maternal race/ethnicity (in categories), maternal weight at time of sample collection (continuous; obtained from screening program records), parity (as 0 for no prior live births or 1 for one or more prior live births), and maternal education (in categories). Categorical variables were modeled using the "class" statement in SAS (SAS Institute Inc.). Separate categories were used for missing covariate data ($\sim 1\%$ or less of each study group for maternal education and race/ethnicity). Adjustment for child gestational age (obtained from screening records), and child birth weight (continuous), paternal age (continuous), and maternal birthplace (as in the United States, Mexico, or outside the United States or Mexico) did not impact results (e.g., did not change the estimate $< 10\%$, a criterion used across analyses for deeming whether results differed; furthermore, gestational age and birthweight may be on the causal pathway); thus, these covariates were not included in final models. Secondarily, we also explored adjustment for PCBs, which were associated with ASD in a previous analysis of the same study population ([@c47]). Tests of trend were conducted using an ordinal variable defined according to the median analyte level of each quartile, with significance determined by a Wald test ($p < 0.05$) in the adjusted models. We also examined whether odds of ASD may differ according to presence of co-occurring intellectual disability by modeling ASD with and without intellectual disability separately, relative to GP controls. Separately, we also examined odds of ID relative to GP controls in parallel analyses.

Stratified analyses were conducted to examine potential effect modification of the association between BFRs and ASD by child sex, given suggestions of potentially sexually dimorphic effects from animal studies ([@c18]; [@c44]; [@c34]; [@c62]). Tests of interaction were conducted using a Wald test for the product of sex by the congener (using the median-value quartile variable; again, $p < 0.05$ was used to define statistical significance).

Sensitivity Analyses {#s2.5}
--------------------

A number of sensitivity analyses were conducted to assess robustness of results. First, we examined the effect of excluding from the ASD group individuals originally identified as ID but classified as ASD following expert review ($n = 132$). Conditional logistic regression analyses (e.g., stratified by matching factors rather than adjusting for them as in primary logistic regression analyses) were conducted within the subset of matched ASD-GP pairs ($n = 826$, including 413 pairs) to examine the impact of breaking the matching and including reclassified ID cases in the ASD group in primary analyses. We also considered alternate strategies for replacing values $< \text{LOD}$ (for congeners detected in at least 55% of samples); these included using lab-read values for low sample volumes originally censored to $< \text{LOD}$ (uncensored data) and multiple imputation using SAS PROC MI ([@c61]). Data used to impute missing values included all chemicals assessed, diagnostic status (ASD, ID, and GP), and covariates previously mentioned as potential confounders. We also examined whether removing those individuals with values $< \text{LOD}$ (rather than imputing their values as in primary analysis) altered results. Finally, we tested whether adjustment for genetic ancestry of mothers, as measured by principal components (PCs) derived from genome-wide association study (GWAS) data, altered results. Details of GWAS and ancestry analyses in EMA are further described in another publication ([@c69]); briefly, genome-wide multi-dimensional scaling (MDS) analysis was carried out on high-quality markers genotyped in maternal cell-pellet samples stored from the XAFP and in newborn samples collected through newborn screening, using a pairwise distance genomic matrix and the multi-dimensional scale functions implemented in PLINK software ([@c54]) (--cluster and --mds plot). The resulting maternal and fetal genetic matrices included 10 PCs that summarized the genetic distance between each maternal and neonatal sample. The top two PCs, which accounted for the majority of variation, were used in ancestry-adjusted models here. PC-adjusted models included other potential confounders described above, with the exception of race/ethnicity, which would be accounted for by the PCs. Adjustment for PCs was not conducted for the ID to GP comparisons because genetic information was available only for the ASD and GP groups.

Results {#s3}
=======

Comparing basic characteristics of the study groups, the mean maternal age was higher, and there was a greater proportion of non-Hispanic whites and more highly educated mothers, in the ASD group compared with the ID or GP groups, whereas higher parity, lower maternal education, Hispanic ethnicity, maternal birth place in Mexico, use of a government insurance program, and higher proportion of preterm and low-birth-weight babies were all more common in the ID group relative to the others ([Table 1](#t1){ref-type="table"}). The higher proportion of males in the ASD and GP groups is a result of an original design feature of the EMA study, wherein cases and controls were matched on sex (as well as birth month and birth year). Of the 10 BFR congeners measured, 6 (BB153, BDE-28, -47, -99, -100, and -153) met our detection rate cutoff. In general, congener detection rates were similar across diagnostic groups, though rates were significantly lower in ASD cases than GP controls for BDE-85 (35% vs. 44%), -99 (92% vs. 96%), and -100 (93% vs. 96%) ([Table 2](#t2){ref-type="table"}). Levels of congeners measured here were in line with ranges reported for all females in the National Health and Nutrition Examination Survey (survey years 2003--2004, partially overlapping with EMA birth years), though geometric means were somewhat lower than those reported from a sample of U.S. pregnant women during the same time period ([@c72]) (see Table S1).

###### 

Characteristics of the study population by diagnostic group.

Table 1 lists characteristics in the first column; the corresponding n values for ASD, ID, and GP are listed in the other columns.

  Characteristic                                          ASD($\mathit{n} = 545$)   ID($\mathit{n} = 181$)   GP($\mathit{n} = 418$)
  ------------------------------------------------------- ------------------------- ------------------------ ------------------------
  Maternal age \[mean (SD)\]                              29.9 (5.6)                27.2 (6.3)               28.7 (5.4)
  Paternal age \[mean (SD)\]                              35.7 (14.6)               36.9 (21.2)              34.0 (14.2)
  Total no. live births \[mean (SD)\]                     1.8 (0.9)                 2.3 (1.5)                2.1 (1.0)
  Parity \[$n$ (%)\][^*a*^](#t1n1){ref-type="table-fn"}                                                       
   Primiparous                                            247 (45%)                 62 (34%)                 159 (38%)
   Multiparous                                            298 (55%)                 119 (66%)                259 (62%)
  Maternal age categories \[$n$ (%)\]                                                                         
   $< 35\; y$                                             442 (81%)                 159 (88%)                366 (88%)
   $\geq 35\; y$                                          103 (19%)                 22 (12%)                 52 (13%)
  Maternal weight at sample collection \[$n$ (%)\]                                                            
   $\leq 127\,\text{lbs}$                                 143 (26%)                 33 (18%)                 110 (26%)
   $128–145\,\text{lbs}$                                  136 (25%)                 41 (23%)                 114 (27%)
   $146–169\,\text{lbs}$                                  135 (25%)                 52 (29%)                 95 (23%)
   $\geq 170\,\text{lbs}$                                 131 (24%)                 55 (30%)                 99 (24%)
  Maternal birth place \[$n$ (%)\]                                                                            
   United States                                          272 (50%)                 79 (44%)                 202 (48%)
   Mexico                                                 131 (24%)                 84 (46%)                 128 (31%)
   Other                                                  142 (26%)                 18 (10%)                 88 (21%)
  Maternal race/ethnicity \[$n$ (%)\]                                                                         
   Non-Hispanic white                                     192 (35%)                 32 (18%)                 138 (33%)
   Asian                                                  82 (15%)                  9 (5%)                   45 (11%)
   Black, Pacific Islander and other                      48 (9%)                   13 (7%)                  35 (8%)
   Hispanic                                               218 (40%)                 126 (70%)                197 (47%)
   Missing                                                5 (1%)                    1 (0.6%)                 3 (0.7%)
  Maternal education \[$n$ (%)\]                                                                              
   Less than high school                                  97 (18%)                  76 (42%)                 102 (24%)
   High school                                            118 (22%)                 50 (28%)                 113 (27%)
   Some college/college degree                            222 (41%)                 42 (23%)                 143 (34%)
   Post-graduate                                          100 (18%)                 11 (6%)                  56 (13%)
   Missing                                                8 (1.5%)                  2 (1%)                   4 (1%)
  Insurance status at delivery \[$n$ (%)\]                                                                    
   Self and other                                         19 (3%)                   7 (4%)                   18 (4%)
   Private insurance                                      289 (53%)                 49 (27%)                 207 (50%)
   Government program                                     237 (43%)                 125 (69%)                193 (46%)
  Child sex                                                                                                   
   Male                                                   446 (82%)                 104 (57%)                345 (83%)
   Female                                                 99 (18%)                  77 (43%)                 73 (17%)
  Child preterm ($< 37\;{wk}$) \[$n$ (%)\]                66 (13%)                  37 (22%)                 44 (11%)
  Child low birth weight ($< 2,500\; g$) \[$n$ (%)\]      42 (8%)                   40 (22%)                 21 (5%)

Note: ASD, autism spectrum disorder; GP, general population controls; ID, intellectual disability/developmental delay without autism.

Defined according to total live births.

###### 

Serum brominated flame retardant (BFR) congener limit of detection information in the Early Markers for Autism study, by case status and sex.

Table 2 lists congeners in the first column. The corresponding LOD range, maximum lipid weight in nanograms per gram, and percentage greater than LOD for full study group (N equals 1,144), n (percentage) greater than LOD values for ASD (n equals 545), ID (n equals 181), and GP (n equals 418) are listed in the following columns. Percentage greater than LOD values for males (n equals 895) and females (n equals 249) are listed in the last two columns.

  BFR       Full study group ($N = 1,144$)   $\mathit{n}\left( \% \right) > \text{LOD}$   $\% > \text{LOD}$                                                                            
  --------- -------------------------------- -------------------------------------------- ------------------- --------------------------------------------- ---------- ---------- ---- ----
  BB153     0.3--1.5                         62.8                                         62                  322 (63)                                      85 (53)    241 (63)   65   56
  BDE-17    0.3--1.6                         6.2                                          2                   8 (2)                                         1 (1)      8 (2)      2    1
  BDE-28    0.3--1.5                         24.1                                         55                  264 (53)                                      82 (53)    220 (59)   58   56
  BDE-47    0.4--8.8                         1000                                         98                  534 (98)                                      178 (98)   410 (99)   98   99
  BDE-66    0.3--1.6                         9.4                                          1                   7 (1)                                         0          8 (2)      1    2
  BDE-85    0.3--1.7                         44.3                                         39                  177 (35)[^*a*^](#t2n1){ref-type="table-fn"}   65 (41)    168 (44)   42   42
  BDE-99    0.4--3.5                         331                                          94                  488 (92)[^*a*^](#t2n1){ref-type="table-fn"}   167 (95)   390 (96)   94   95
  BDE-100   0.3--2.3                         271                                          95                  497 (93)[^*a*^](#t2n1){ref-type="table-fn"}   173 (98)   390 (96)   96   95
  BDE-153   0.3--2.6                         249                                          95                  504 (95)                                      168 (95)   389 (96)   95   96
  BDE-154   0.3--1.6                         38.5                                         39                  178 (35)                                      62 (39)    166 (43)   42   43

Significant difference in detection rates according to chi-squared test comparing ASD to GP. (No significant differences in detection rates were found comparing ID with GP.)

Geometric mean concentrations of lipid-adjusted BFRs were lower in ASD cases than GP controls for five of the six of the congeners detected in $\geq 55\%$ of samples (all BDE congeners), as well as for the sum of these six congeners ([Table 3](#t3){ref-type="table"}). Levels in the ID group were lower than levels in the GP controls for all congeners detected in $\geq 55\%$ of samples. Comparing ID to ASD, levels in the ID group were higher for BDE-47, -99, and -100 than levels in the ASD group. With the exception of BB153, all congeners demonstrated strong and significant correlations between one another ($r$ 0.54--0.99, *p*-values $< 0.001$; see Table S2).

###### 

Geometric mean brominated flame retardant congener serum concentrations (in ng/g lipid) and 95% confidence intervals from mid-pregnancy samples in the Early Markers for Autism study by diagnostic group.

Table 3 lists compound in the first column; the corresponding n values for the full study group (n equals 1,144), ASD (n equals 545), ID (n equals 181), and GP (n equals 418). The p-values for ASD versus GP and ID versus GP are listed in the last 2 columns separately.

  BFR                                      Full study group    ASD                 ID                  GP                  ASD vs. GP   ID vs. GP
  ---------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------ -----------
  BB153                                    1.15 (1.09, 1.22)   1.21 (1.12, 1.31)   1.02 (0.90, 1.17)   1.14 (1.04, 1.25)   0.30         0.20
  BDE-28                                   0.89 (0.85, 0.93)   0.87 (0.82, 0.92)   0.84 (0.77, 0.93)   0.94 (0.88, 1.02)   0.26         0.07
  BDE-47                                   16.0 (15.1, 17.0)   14.7 (13.4, 16.0)   16.3 (14.2, 18.7)   17.9 (16.2, 19.7)   0.002        0.29
  BDE-99                                   4.93 (4.63, 5.24)   4.45 (4.01, 4.87)   5.15 (4.47, 5.94)   5.52 (4.98, 6.11)   0.002        0.46
  BDE-100                                  3.94 (3.71, 4.19)   3.59 (3.28, 3.93)   3.91 (3.45, 4.44)   4.48 (4.05, 4.95)   0.002        0.10
  BDE-153                                  4.34 (4.08, 4.62)   4.02 (3.67, 4.40)   3.91 (3.41, 4.48)   5.02 (4.51, 5.58)   0.002        0.004
  Sum[^*a*^](#t3n1){ref-type="table-fn"}   34.9 (32.9, 36.9)   32.1 (29.5, 34.9)   32.6 (28.6, 37.2)   40.1 (36.4, 44.2)   0.0006       0.02

Note: ASD, autism spectrum disorder; BDE, polybrominated diphenyl ether; GP, general population controls; ID, intellectual disability/developmental delay without autism. Table shows geometric means following replacement of values $< \text{LOD}$ with LOD divided by the square root of 2 as described in the text. For descriptive data by sex, see Table S8.

Sum is the sum of all congeners shown in table (e.g., those meeting our detection rate of at least 55% of the study population with concentrations $> \text{LOD}$).

When examining odds of ASD according to quartiles, individuals in higher quartiles of all BFR congeners, except BB153, had reduced odds of ASD relative to those in the lowest quartile, in analyses adjusted for the matching factors only (Model 1) and adjusted analyses (Model 2) ([Table 4](#t4){ref-type="table"}). In adjusted models, individuals in the third-fourth quartiles of levels of BDE-47, -99, and -100 had approximately a 30% reduction in odds of having a child with ASD; of these, only BDE-100 demonstrated a significant inverse association with ASD odds (for quartiles 2 and 3, though estimates were nearly identical across quartiles 2--4). Slightly stronger inverse associations were observed for the highest quartiles of BDE-153 ($\text{AOR} = 0.56$; 95% CI: 0.38, 0.84) as well as the BFR sum ($\text{AOR} = 0.64$; 95% CI: 0.44, 0.93). Tests of trend of BDE-153 and the combined BFR were also statistically significant, though the pattern of estimates across quartiles was not monotonic. Additional adjustment for gestational age, maternal country of birth, child birth weight, PCB levels, and other covariates available including paternal age and insurance status did not impact results (data not shown). Exploring other sums of congeners (as detailed in "Methods") yielded similar estimates as the sum of congeners meeting our detection rate cutoff (see Table S3).

###### 

Odds ratios and 95% confidence intervals for associations between quartiles of prenatal brominated flame retardant serum concentrations and ASD (relative to GP controls).

Table 4 lists congeners in the first column; the corresponding PBDE concentration, cases, control, model 1, model 2, and p for trend are listed in the other columns.

  BFR/quartile                             PBDE concentration[^*a*^](#t4n1){ref-type="table-fn"}   Case[^*b*^](#t4n2){ref-type="table-fn"} ($n$)   Control ($n$)   Model 1[^*c*^](#t4n3){ref-type="table-fn"}   Model 2[^*d*^](#t4n4){ref-type="table-fn"}   *p*-Trend[^*e*^](#t4n5){ref-type="table-fn"}
  ---------------------------------------- ------------------------------------------------------- ----------------------------------------------- --------------- -------------------------------------------- -------------------------------------------- ----------------------------------------------
  BB153                                                                                                                                                                                                                                                       
   Q1                                      $\leq 0.5$                                              114                                             93              1.0                                          1.0                                          0.86
   Q2                                      0.51--1.06                                              124                                             92              1.10 (0.75, 1.61)                            1.14 (0.76, 1. 70)                            
   Q3                                      1.07--1.80                                              117                                             100             0.96 (0.65, 1.40)                            0.86 (0.56, 1.31)                             
   Q4                                      $> 1.80$                                                154                                             98              1.28 (0.88, 1.86)                            1.12 (0.73, 1.71)                             
  BDE-28                                                                                                                                                                                                                                                      
   Q1                                      $\leq 0.49$                                             142                                             94              1.0                                          1.0                                          0.31
   Q2                                      0.5--0.8                                                130                                             93              0.92 (0.64, 1.34)                            0.95 (0.65, 1.39)                             
   Q3                                      0.81--1.30                                              114                                             90              0.84 (0.57, 1.23)                            0.89 (0.60, 1.31)                             
   Q4                                      $> 1.3$                                                 116                                             99              0.77 (0.53, 1.13)                            0.82 (0.56, 1.22)                             
  BDE-47                                                                                                                                                                                                                                                      
   Q1                                      $\leq 9.2$                                              178                                             103             1.0                                          1.0                                          0.07
   Q2                                      9.3--16.8                                               134                                             105             0.74 (0.52, 1.05)                            0.77 (0.53, 1.10)                             
   Q3                                      16.9--31.5                                              116                                             104             0.64 (0.45, 0.92)                            0.71 (0.49, 1.02)                             
   Q4                                      $> 31.5$                                                117                                             104             0.65 (0.45, 0.93)                            0.73 (0.50, 1.05)                             
  BDE-99                                                                                                                                                                                                                                                      
   Q1                                      $\leq 2.7$                                              183                                             107             1.0                                          1.0                                          0.05
   Q2                                      2.8--4.8                                                117                                             100             0.71 (0.50, 1.02)                            0.75 (0.52, 1.08)                             
   Q3                                      4.9--9.7                                                145                                             102             0.64 (0.44, 0.92)                            0.72 (0.49, 1.04)                             
   Q4                                      $> 9.7$                                                 88                                              98              0.61 (0.42, 0.87)                            0.70 (0.48, 1.01)                             
  BDE-100                                                                                                                                                                                                                                                     
   Q1                                      $\leq 2.1$                                              181                                             99              1.0                                          1.0                                          0.05
   Q2                                      2.2--3.8                                                116                                             102             0.62 (0.43, 0.89)                            0.66 (0.45, 0.95)                             
   Q3                                      3.9--7.5                                                120                                             103             0.63 (0.44, 0.91)                            0.68 (0.47, 0.98)                             
   Q4                                      $> 7.5$                                                 116                                             103             0.61 (0.43, 0.88)                            0.69 (0.47, 1.00)                             
  BDE-153                                                                                                                                                                                                                                                     
   Q1                                      $\leq 2.3$                                              179                                             95              1.0                                          1.0                                          0.01
   Q2                                      2.4--4.1                                                116                                             103             0.60 (0.42, 0.86)                            0.62 (0.43, 0.90)                             
   Q3                                      4.2--8.8                                                134                                             107             0.66 (0.46, 0.95)                            0.71 (0.49, 1.03)                             
   Q4                                      $> 8.8$                                                 104                                             102             0.54 (0.37, 0.78)                            0.56 (0.38, 0.84)                             
  Sum[^*f*^](#t4n6){ref-type="table-fn"}                                                                                                                                                                                                                     0.01
   Q1                                      $\leq 20.2$                                             166                                             94              1.0                                          1.0                                           
   Q2                                      $> 20.2–35.1$                                           118                                             94              0.82 (0.58, 1.16)                            0.83 (0.58, 1.18)                             
   Q3                                      35.1--70.5                                              134                                             94              0.93 (0.66, 1.31)                            1.01 (0.71, 1.44)                             
   Q4                                      $\geq 70.5$                                             84                                              94              0.58 (0.40, 0.84)                            0.64 (0.44, 0.93)                             

Note: ASD, autism spectrum disorder; GP, general population controls.

Lipid-adjusted concentration in ng/g lipid, categorized into quartiles based on control distribution.

Columns show number of cases and controls, respectively, in the quartile.

Model 1: logistic regression adjusted for study matching factors (child sex, month and year of birth).

Model 2: $\text{Model}\, 1 + \text{maternal}\,\text{age}$ (continuous), maternal race/ethnicity (non-Hispanic white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at time of sample collection (quartiles), parity (multi- vs. primiparous), and maternal education ($< \text{high}\,\text{school}$, high school, college, graduate).

*p*-Trend from model with quartile median-value variable, adjusted as Model 2.

Sum of all congeners shown in this table (those with at least 55% of study population with values $> \text{LOD}$).

Analyses of odds of ID produced a similar pattern of results to those seen for ASD. Given the smaller number of ID cases, these associations were not as precise as for ASD, but for all congeners higher levels were associated with reductions in odds of ID, except for BB153 and BDE-28 ([Table 5](#t5){ref-type="table"}).

###### 

Odds ratios and 95% confidence intervals for associations between quartiles of prenatal brominated flame retardant serum concentrations and ID (relative to GP controls).

Table 5 lists congeners in the first column; the corresponding ID number, control, model 1, model 2, and p for trend are listed in the other columns.

  BFR/quartile                             ID ($n$)   Control ($n$)   Model 1[^*a*^](#t5n1){ref-type="table-fn"}   Model 2[^*b*^](#t5n2){ref-type="table-fn"}   *p*-Trend[^*c*^](#t5n3){ref-type="table-fn"}
  ---------------------------------------- ---------- --------------- -------------------------------------------- -------------------------------------------- ----------------------------------------------
  BB153                                                                                                                                                          
   Q1                                      41         93              1.0                                          1.0                                          0.62
   Q2                                      52         92              1.21 (0.72, 2.05)                            1.46 (0.84, 2.54)                             
   Q3                                      30         100             0.71 (0.40, 1.26)                            0.95 (0.51, 1.79)                             
   Q4                                      37         98              0.84 (0.48, 1.45)                            1.34 (0.72, 2.51)                             
  BDE-28                                                                                                                                                         
   Q1                                      38         94              1.0                                          1.0                                          0.95
   Q2                                      47         93              1.24 (0.72, 2.13)                            1.30 (0.73, 2.31)                             
   Q3                                      34         90              0.97 (0.55, 1.73)                            1.00 (0.54, 1.82)                             
   Q4                                      36         99              1.06 (0.60, 1.86)                            1.12 (0.62, 2.04)                             
  BDE-47                                                                                                                                                         
   Q1                                      46         103             1.0                                          1.0                                          0.30
   Q2                                      52         105             1.09 (0.66, 1.81)                            1.04 (0.62, 1.77)                             
   Q3                                      48         104             1.06 (0.63, 1.77)                            0.93 (0.54, 1.58)                             
   Q4                                      35         104             0.81 (0.47, 1.38)                            0.76 (0.43, 1.34)                             
  BDE-99                                                                                                                                                         
   Q1                                      46         107             1.0                                          1.0                                          0.14
   Q2                                      46         100             0.93 (0.56, 1.55)                            0.87 (0.51, 1.49)                             
   Q3                                      48         102             1.06 (0.64, 1.78)                            0.85 (0.50, 1.46)                             
   Q4                                      36         98              0.75 (0.44, 1.29)                            0.64 (0.36, 1.13)                             
  BDE-100                                                                                                                                                        
   Q1                                      46         99              1.0                                          1.0                                          0.55
   Q2                                      45         102             0.89 (0.53, 1.50)                            0.86 (0.50, 1.48)                             
   Q3                                      50         103             1.07 (0.65, 1.79)                            1.02 (0.60, 1.73)                             
   Q4                                      35         103             0.77 (0.45, 1.32)                            0.78 (0.44, 1.37)                             
  PBDE153                                                                                                                                                        
   Q1                                      53         95              1.0                                          1.0                                          0.56
   Q2                                      48         103             0.93 (0.56, 1.53)                            1.01 (0.60, 1.70)                             
   Q3                                      41         107             0.74 (0.44, 1.24)                            0.83 (0.49, 1.42)                             
   Q4                                      34         102             0.71 (0.41, 1.20)                            0.90 (0.51, 1.62)                             
  Sum[^*d*^](#t5n4){ref-type="table-fn"}                                                                                                                         
   Q1                                      45         94              1.0                                          1.0                                          0.14
   Q2                                      42         94              0.84 (0.52, 1.37)                            0.87 (0.52, 1.43)                             
   Q3                                      44         94              0.91 (0.56, 1.47)                            0.87 (0.53, 1.43)                             
   Q4                                      24         94              0.53 (0.31, 0.92)                            0.58 (0.33, 1.03)                             

Note: GP, general population controls; ID, intellectual disability/developmental delay without autism.

Model 1: logistic regression adjusted for study matching factors (child sex, month and year of birth).

Model 2: $\text{Model}\, 1 + \text{maternal}\,\text{age}$ (continuous), maternal race/ethnicity (non-Hispanic white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at time of sample collection (quartiles), parity (multi- vs. primiparous), and maternal education ($< \text{high}\,\text{school}$, high school, college, graduate, missing).

*p*-Trend from the median value variable, adjusted as Model 2.

Sum of all congeners shown in this table (those with at least 55% of study population with values $> \text{LOD}$).

Analyses parameterizing BFR concentrations continuously suggested generally null associations or modest reductions in odds of ASD associated with higher BFR levels. With the exception of BDE-153, which was associated with a 9% decrease in odds of ASD with each 10-fold increase in serum concentration ($\text{AOR} = 0.91$; 95% CI: 0.83, 0.99), these associations were not statistically significant ([Table 6](#t6){ref-type="table"}). As for quartile analyses, associations with ID were similar to those seen for ASD, with all estimates below the null.

###### 

Odd ratios and 95% confidence intervals for associations of ASD and ID (relative to GP controls) with 10-fold increases in brominated flame retardant concentrations from maternal serum samples (ng/g lipid).

Table 6 lists congeners in the first column; the corresponding adjusted model 1, adjusted model 2, and p-value are listed in the other columns.

  BFR                                       Adjusted Model 1[^*a*^](#t6n1){ref-type="table-fn"}   Adjusted Model 2[^*b*^](#t6n2){ref-type="table-fn"}   *p*-Value[^*c*^](#t6n3){ref-type="table-fn"}
  ----------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------
  ASD                                                                                                                                                   
   BB153                                    1.00 (0.75, 1.33)                                     0.97 (0.73, 1.30)                                     0.85
   BDE-28                                   0.54 (0.25, 1.19)                                     0.58 (0.26, 1.27)                                     0.17
   BDE-47                                   0.98 (0.96, 1.00)                                     0.99 (0.97, 1.01)                                     0.19
   BDE-99                                   0.97 (0.92, 1.01)                                     0.97 (0.93, 1.02)                                     0.24
   BDE-100                                  0.94 (0.86, 1.02)                                     0.95 (0.87, 1.02)                                     0.17
   BDE-153                                  0.91 (0.83, 0.99)                                     0.91 (0.83, 0.99)                                     0.02
   Sum[^*d*^](#t6n4){ref-type="table-fn"}   0.99 (0.98, 1.00)                                     0.99 (0.98, 1.00)                                     0.10
  ID                                                                                                                                                    
   BB153                                    0.74 (0.37, 1.49)                                     0.98 (0.55, 1.75)                                     0.95
   BDE-28                                   0.23 (0.04, 1.24)                                     0.24 (0.04, 1.25)                                     0.09
   BDE-47                                   0.98 (0.95, 1.02)                                     0.98 (0.95, 1.02)                                     0.27
   BDE-99                                   0.95 (0.87, 1.03)                                     0.94 (0.87, 1.03)                                     0.17
   BDE-100                                  0.83 (0.68, 1.02)                                     0.84 (0.68, 1.04)                                     0.11
   BDE-153                                  0.81 (0.67, 0.99)                                     0.88 (0.73, 1.07)                                     0.21
   Sum[^*d*^](#t6n4){ref-type="table-fn"}   0.98 (0.95, 1.00)                                     0.98 (0.95, 1.00)                                     0.09

Model 1: logistic regression adjusted for study matching factors (child sex, month and year of birth).

Model 2: $\text{Model}\, 1 + \text{maternal}\,\text{age}$ (continuous), maternal race/ethnicity (non-Hispanic white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at time of sample collection (quartiles), parity (multi- vs. primiparous), and maternal education ($< \text{high}\,\text{school}$, high school, college, graduate).

*p*-Value for BFR coefficient from adjusted model 2.

Sum of all congeners shown in this table (e.g., those with at least 55% of study population with values $> \text{LOD}$).

When examining BFRs in association with ASD with or without intellectual disability, results were generally consistent with those for ASD overall (see Table S4). Results were also stable across various sensitivity analyses performed (see Table S5), with point estimates and the pattern of results similar to primary analyses when using uncensored laboratory data (numbers shown in Table S6), multiple imputation to replace values $< \text{LOD}$, removing the group of individuals originally classified as ID but later determined to meet criteria for ASD, conducting matched analyses using conditional logistic regression, or adding adjustment for genetic ancestry PCs. Estimates were somewhat more variable when removing individuals with values $< \text{LOD}$, especially for BDE-28 (as this congener had the greatest proportion of individuals $< \text{LOD}$); however, point estimates remained below the null. Due to the unexpected overall findings, we also explored alternate paramterizations and categorizations of BFRs. Cubic spline analyses suggested relationships between the congeners and ASD, if any, were linear (and tests of nonlinearity were not significant), with decreases in odds of ASD with higher BFR levels that were not statistically significant except for BDE-153 (see Figure S1). Examining high and low extremes of the distribution of BFR concentrations relative to those with levels in the middle range yielded results generally consistent with those suggested in primary analyses, with nonsignificant reductions in odds of ASD associated with BDEs in the $> 90\text{th}\,\text{percentiles}$, and increases in odds of ASD for those in the lowest 10th percentile (and particularly lowest 5th percentile) of BDEs and the sum, as compared with those with concentrations in the mid 11th--89th percentiles (see Table S7).

Results by Sex {#s3.1}
--------------

As a consequence of original matching of ASD to GP, and including individuals reclassified from ID to ASD following expert review of records within our ASD analysis group (as described in "Methods"), there were 99, 77, and 73 girls with ASD, ID, and GP, respectively, and 446, 104, and 354 boys with these outcomes ([Table 1](#t1){ref-type="table"}). Detection frequencies were similar between male and female offspring ([Table 2](#t2){ref-type="table"}). Geometric mean concentrations were higher for BDE congeners for ASD and ID girls than for boys in these groups (see Table S8).

In analyses of ASD stratified by sex, ORs from quartile models of BB153 were generally close to the null and similar between boys and girls (interaction $p - \text{value} = 0.83$, [Table 7](#t7){ref-type="table"}). Estimates for all BDE congeners were below the null for boys ([Table 7](#t7){ref-type="table"}), and comparing the highest to the lowest quartile, were significant for all BDEs except BDE-28 ([Figure 1](#f1){ref-type="fig"}). Overall, the estimates for boys were consistent with those for the population as a whole, as expected given that boys accounted for most of the ASD and GP observations. In contrast, ORs comparing ASD in the highest and lowest quartiles of BDE exposures in girls were above the null ([Figure 1](#f1){ref-type="fig"}). Interaction *p*-values were significant for all BDE congeners, though estimates in girls were imprecise due to small numbers, and patterns for lower quartiles were inconsistent ([Table 7](#t7){ref-type="table"}).

###### 

Odds ratios and 95% confidence intervals for quartiles of prenatal brominated flame retardant congener serum concentrations in association with ASD (relative to GP controls), stratified by child sex.

Table 7 lists congeners in the first column; the corresponding case or control number, model 1, and model 2 for males and females are listed in the following columns separately. The p-value for interaction is listed in the last column.

  BFR/quartile                             Males    Females             *p*-Interaction[^*a*^](#t7n1){ref-type="table-fn"}                                                   
  ---------------------------------------- -------- ------------------- ---------------------------------------------------- ------- ------------------- ------------------- ------
  BB153                                                                                                                                                                      0.83
   Q1                                      93/76    1.0                 1.0                                                  21/17   1.0                 1.0                  
   Q2                                      95/74    1.05 (0.68, 1.61)   1.12 (0.72, 1. 75)                                   29/18   1.32 (0.55, 3.18)   1.27 (0.48, 3.37)    
   Q3                                      100/85   0.96 (0.63, 1.46)   0.85 (0.53, 1.36)                                    17/15   0.93 (0.36, 2.40)   0.99 (0.31, 3.20)    
   Q4                                      130/81   1.31 (0.87, 1.99)   1.10 (0.72, 1. 69)                                   24/17   1.17 (0.47, 2.89)   1.19 (0.37, 3.78)    
  BDE-28                                                                                                                                                                     0.02
   Q1                                      122/76   1.0                 1.0                                                  20/18   1.0                 1.0                  
   Q2                                      104/74   0.87 (0.58, 1.32)   0.94 (0.61, 1.44)                                    26/19   1.23 (0.52, 2.96)   0.92 (0.34, 2.46)    
   Q3                                      95/72    0.82 (0.54, 1.25)   0.91 (0.59, 1.40)                                    19/18   0.96 (0.39, 2.41)   0.70 (0.25, 2.00)    
   Q4                                      92/89    0.64 (0.42, 0.97)   0.70 (0.45, 1.07)                                    24/10   2.20 (0.82, 5.92)   2.58 (0.86, 7.79)    
  BDE-47                                                                                                                                                                     0.02
   Q1                                      152/81   1.0                 1.0[^\*^](#t7n5){ref-type="table-fn"}                26/22   1.0                 1.0^+^               
   Q2                                      108/89   0.64 (0.44, 0.95)   0.70 (0.47, 1.04)                                    26/16   1.37 (0.59, 3.19)   1.31 (0.50, 3.43)    
   Q3                                      95/82    0.61 (0.41, 0.92)   0.69 (0.47, 1.00)                                    21/22   0.78 (0.34, 1.81)   0.89 (0.34, 2.31)    
   Q4                                      91/91    0.53 (0.36, 0.79)   0.72 (0.50, 1.05)                                    26/13   1.66 (0.69, 4.00)   2.64 (0.97, 7.19)    
  BDE-99                                                                                                                                                                     0.04
   Q1                                      150/80   1.0                 1.0[^\*^](#t7n5){ref-type="table-fn"}                27/20   1.0                 1.0                  
   Q2                                      111/85   0.69 (0.47, 1.03)   0.74 (0.50, 1.11)                                    19/18   0.77 (0.32, 1.85)   0.86 (0.32, 2.30)    
   Q3                                      87/83    0.55 (0.37, 0.83)   0.61 (0.40, 0.93)                                    29/19   1.13 (0.50, 2.58)   1.81 (0.70, 4.69)    
   Q4                                      88/88    0.53 (0.36, 0.79)   0.60 (0.39, 0.90)                                    22/14   1.16 (0.48, 2.82)   1.98 (0.71, 5.56)    
  BDE-100                                                                                                                                                                    0.03
   Q1                                      151/80   1.0                 1.0[^\*^](#t7n5){ref-type="table-fn"}                30/19   1.0                 1.0                  
   Q2                                      101/81   0.66 (0.44, 0.98)   0.72 (0.48, 1.08)                                    15/21   0.45 (0.19, 1.08)   0.51 (0.19, 1.38)    
   Q3                                      92/86    0.57 (0.38, 0.84)   0.61 (0.40, 0.91)                                    28/17   1.05 (0.45, 2.44)   1.56 (0.59, 4.17)    
   Q4                                      92/89    0.55 (0.37, 0.81)   0.61 (0.40, 0.92)                                    24/14   1.09 (0.45, 2.62)   1.62 (0.59, 4.42)    
  BDE-153                                                                                                                                                                    0.02
   Q1                                      152/72   1.0                 1.0[^\*^](#t7n5){ref-type="table-fn"}                27/23   1.0                 1.0                  
   Q2                                      90/88    0.48 (0.32, 0.73)   0.48 (0.32, 0.73)                                    26/15   1.48 (0.64, 3.44)   2.12 (0.82, 5.52)    
   Q3                                      111/87   0.61 (0.41, 0.90)   0.64 (0.43, 0.97)                                    23/20   0.96 (0.42, 2.20)   1.20 (0.45, 3.23)    
   Q4                                      83/89    0.44 (0.29, 0.67)   0.45 (0.29, 0.70)                                    21/13   1.35 (0.55, 3.31)   2.04 (0.71, 5.84)    
  Sum[^*d*^](#t7n4){ref-type="table-fn"}                                                                                                                                     0.03
   Q1                                      143/75   1.0                 1.0[^\*^](#t7n5){ref-type="table-fn"}                29/20   1.0                 1.0                  
   Q2                                      90/78    0.79 (0.54, 1.16)   0.82 (0.55, 1.22)                                    22/17   0.94 (0.42, 2.09)   1.03 (0.41, 2.59)    
   Q3                                      117/78   0.92 (0.63, 1.35)   1.02 (0.69, 1.50)                                    22/17   0.91 (0.41, 2.05)   1.28 (0.51, 3.20)    
   Q4                                      68/85    0.52 (0.35, 0.78)   0.57 (0.37, 0.86)                                    16/11   1.04 (0.42, 2.57)   1.42 (0.51, 3.98)    

Note: GP, general population.

*p*-Interaction term for BFR concentration (ordinal median value variable) by sex, adjusted as in Model 2, including males and females.

Model 1: logistic regression adjusted for child month and year of birth.

Model 2 (estimates as shown in [Figure 1](#f1){ref-type="fig"}): $\text{Model}\, 1 + \text{maternal}\,\text{age}$, maternal race/ethnicity, maternal weight at time of sample collection, parity, and maternal education.

Sum of congeners listed in table (detected in $> 55\%$ of the study population).

$p < 0.05$ in test for trend across quartiles.

![Adjusted odds ratio (AOR) estimates from logistic regression for ASD relative to GP comparing those with in highest quartile of the BFR congener levels to the lowest (referent) quartile, adjusted for maternal age, education, race/ethnicity, weight, parity, and child year and month of birth (e.g., as in [Table 3](#t3){ref-type="table"} Model 2, without adjustment for child sex). Diamonds (boys, $n = 446$ ASD cases and 345 GP controls) and circles (girls, $n = 99$ ASD cases and 73 GP controls). Vertical lines indicate 95% confidence intervals. Horizontal line indicates the null value of $\text{OR} = 1$. The *y* axis is log-scaled for symmetry. Numbers of observations, AORs, and 95% confidence intervals for all quartiles are shown in [Table 7](#t7){ref-type="table"}. Sum indicates the sum of congeners shown (those with at least 55% of study population with values $> \text{LOD}$).](EHP1079_f1){#f1}

Differences in associations with ID between boys and girls were generally consistent but less pronounced than those for ASD (see Table S9). Comparing the highest to lowest quartiles, estimates were above the null for girls for BDEs 47, 99, and 100, and null for other congeners, and below the null for boys ([Figure 2](#f2){ref-type="fig"}). Interaction terms for sex by congener levels for ID analyses were not statistically significant (see Table S9).

![Adjusted odds ratio (AOR) estimates for ID relative to GP, adjusted for maternal age, education, race/ethnicity, weight, parity, and child year and month of birth. Diamonds (boys, $\mathit{n} = 104$ ID cases and 345 GP controls) and circles (girls, $\mathit{n} = 77$ ID cases and 73 GP controls). Vertical lines indicate 95% confidence intervals. Horizontal line indicates the null value of $\text{OR} = 1$. The *y* axis is log-scaled for symmetry. Numbers of observations, AORs, and 95% confidence intervals for all quartiles are shown in Table S7. Sum indicates the sum of congeners shown (those with at least 55% of study population with values $> \text{LOD}$).](EHP1079_f2){#f2}

Discussion {#s4}
==========

To our knowledge, this is the first study to examine prenatal BFR exposure in association with ASD and ID. Contrary to expectations, ASD was inversely associated with the highest exposure levels of several congeners, with significant inverse associations estimated for BDE-100, -153, and the sum of BB153 and BDEs-28, 47, -99, -100, and -153. Odds ratios for ID showed similar patterns, but were less precise due to small numbers of cases, and generally closer to the null. However, when we stratified by sex, the inverse associations appeared to be specific to boys, whereas associations for girls (though based on small numbers and thus less precise) were more likely to be above the null.

To date, few other human studies have examined childhood neurodevelopmental effects of prenatal BFR exposure, though the majority of this literature suggests adverse impacts on child neurodevelopment ([@c36]). In an analysis including 323 mother--child pairs of the CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas) study ([@c26]), a longitudinal birth cohort including mostly Mexican-American families from California's Salinas Valley, individuals with the highest quartiles of the sum of 10 PBDEs measured in prenatal serum samples (including some congeners not included in our analysis) had lower attention, fine motor, and verbal comprehension scores at 5 or 7 y. Another study, conducted in Spain, reported nonsignificant inverse associations between pre- (measured in cord blood, $n = 88$) and postnatal (measured in child serum at age 4, $n = 244$) BDE-47 levels when comparing those above with those below the limit of detection and cognitive and motor scores as measured by the McCarthy Scales at age 4 ([@c30]). Additional work by the same group suggested an inverse association between scores on the Bayley Scales of Infant Development and BDE-209 concentrations measured in colostrum ([@c29]). In another study of mothers and children from New York, increases in levels of PBDEs (particularly BDE-47, -99, and -100) measured in cord blood ($n = 210$) were associated with decreases in psychomotor and mental development scores at 12, 24, and 36 mo, and with lower IQ scores at 48 mo ([@c37]).

However, findings have not been consistent across all studies. In an analysis of the Pregnancy, Infection, and Nutrition study of North Carolina including 304 mothers and their children, individuals in the highest quartiles of PBDEs measured in breast milk (including the same BDE congeners included in analyses in our study) had higher scores for anxious behavior, but also higher adaptive and cognitive behavior scale scores as measured by the parent rating scale for preschoolers (age 2--5 y) of the *Behavior Assessment System for Children, 2nd Edition* (BASC-2), relative to those in the lowest quartile of PBDE congeners ([@c1]). In the only study other than ours to our knowledge with prenatal PBDE measurements and ASD outcome information ([@c5]), the HOME Study (Health Outcomes and Measures of the Environment Study), which includes over 400 pregnant women and their children from the Cincinnati, Ohio, area, reported conflicting findings for different congeners measured in prenatal serum samples from 175 of its participants. Increases in BDE-28 were associated with higher SRS scores (indicating more autistic behaviors), and detectable versus nondetectable concentrations of BDE-85 were associated with fewer autistic behaviors. Six other PBDE congeners in the HOME Study had close to null, nonsignificant associations with SRS scores. In another analysis in the HOME Study including 309 participants, a 10-fold increase in BDE-47 was associated with a significantly lower full-scale IQ and significantly higher hyperactivity score at age 5 y, but there were no significant associations for younger ages examined ([@c8]). Differences in study populations, or design (e.g., measuring PBDEs in prenatal serum vs. breast milk) may have contributed to discrepancies in prior literature. California is known to have some of the highest reported serum levels of PBDEs worldwide. Although the levels detected in our study population were lower than some other studies of pregnant women in California and elsewhere ([@c72]; [@c7]; [@c75]), they were similar to those reported in CHAMACOS (also a California study of pregnant women) ([@c26]), as well as the HOME Study (in Ohio) ([@c5]).

The reason for an inverse association between prenatal BFRs and odds of ASD as suggested for some congeners here is not apparent. While adjustment for a large number of factors, including demographic characteristics shown to be predictive of PBDE levels ([@c40]), as well as genetic PCs, did not materially change our results, it is possible that inverse associations may be due to unmeasured confounding by some shared influences on BFR levels and ASD, rather than a true protective association. If higher levels of flame retardants are associated with spontaneous abortion, as suggested in one study of polybrominated biphenyls ([@c65]), this may have influenced the observed associations, particularly if male fetuses are more susceptible to such loss---though this is not clear ([@c53]). It is also possible that such findings are due to chance. Results here could also be consistent with an overall lack of an association with ASD, as suggested by nonsignificant results of continuous analyses for most congeners and some of our sensitivity analyses.

Null findings in other work, along with results here, suggest that prenatal exposure to these BFRs may be unrelated to ASD risk specifically. However, prenatal exposure may influence frequently comorbid features of ASD, such as attention deficits or related impairments in cognitive scores, and these questions should be further explored. Other than examining comorbid ID, we did not have the ability to assess the influence of heterogeneity within ASD, or risk of ASD with other comorbid conditions, and associations could plausibly vary according to phenotypically distinct ASD subgroups.

When examining associations stratified by sex, our study found significant inverse associations with higher brominated PBDEs (BDE-100, -153) in boys, and nonsignificant increases in odds of ASD (particularly for BDE-28, -47) when comparing high with low quartiles of BDEs in girls. In addition, significant interactions with sex were suggested for all BDE congeners. However, patterns over all quartiles were not consistent with monotonic trends, and estimates in girls were imprecise. We cannot place too much emphasis on the results for individual congeners in our stratified analyses, given the high correlation of most PBDE congeners, as well as the smaller numbers of girls in our study as a result of the skewed sex ratio in ASD. However, sex differences in placental functioning ([@c59]), pharmacokinetics, or methylation patterns, supported in prior work ([@c66]; [@c41]) could result in sex-specific effects of BFRs on fetal development. The suggestion of sex differences seen here warrants further consideration, particularly in light of toxicologic evidence from animal models of potential sexually dimorphic effects of these chemicals (Lilienthal et al. 2006; [@c73]; [@c27]), as well as the consistent male-skewed sex ratio for ASD suggesting that risk factors that differ by sex may provide etiologic clues.

In support of such dimorphism, previous studies have suggested sex differences in the effects of prenatal BFR exposure on other outcomes. Associations with child BMI at age 7 y ([@c25]), birth weight ([@c56]), and development of sexually dimorphic brain regions in the rat ([@c27]) were all in opposite directions for males and females. In addition, some studies have suggested developmental impacts in girls, but not boys, in association with other EDCs. In the HOME Study (described above), a stronger association between prenatal bisphenol A exposure measured in maternal samples collected at 16 wk gestation and externalizing behavior at age 2 was noted for girls ([@c6]), though associations were not significant at other time points. Another analysis of the same cohort and maternal serum samples found that only in girls were there greater social deficits with higher levels of one of five prenatal organochlorine pesticides (another class of EDCs) examined ([@c5]). Of over 50 EDCs evaluated, few other sex differences, not all in the same direction, were reported in this study: a positive association with autistic traits as measured by the SRS and serum perfluorooctanesulfonic acid in boys but not girls, and opposing relationships with SRS scores in boys (negative) and girls (positive) with levels of monoethyl phthalate.

Suspected pathways through which BFRs may influence neurodevelopment include disruptions of immune markers, neurotransmitters, or calcium signaling ([@c35]; [@c33]) and through impacts on thyroid hormone levels, which play a known role in neurodevelopment ([@c19]). There is limited animal evidence suggesting that impacts on thyroid hormone levels following exposure to other chemicals may differ between the sexes ([@c67]). Some studies have reported associations between thyroid hormone ([@c71]) or immune markers ([@c2]) and PBDEs only for those congeners (-28 and -47) for which we saw the strongest suggestion for an association with ASD in girls, though these findings are not uniform, with other studies reporting null or nonsignificant associations between PBDE congeners and thyroid hormones, and no differences by sex ([@c11]; [@c46]; [@c22]; [@c30]; [@c26]). Thus, work examining mechanisms by which these chemicals may influence neurodevelopment in humans is still needed and may help elucidate associations.

This study has a number of strengths: measurement of BFR levels during gestation, a time period demonstrated to be critical to neurodevelopment ([@c58]; [@c55]), inclusion of over 500 cases of ASD, and ASD and ID diagnoses confirmed by expert clinician review. However, certain limitations should be noted. A number of congeners were not detected in enough of our study group in order to examine their association with the outcomes of interest, though detection rates ($\% > \text{LOD}$) were similar to those reported in other studies ([@c11]; [@c1]). We lacked information on exposure in other time windows, including during breastfeeding, which, although potentially highly correlated with mid-gestational exposure levels ([@c49]), could also represent critical windows of exposure for ASD and ID risk. Though our sample size was adequate in primary analyses, we had reduced power in analyses of ASD and ID in females. We did not have information on income level, though adjustment for available socioeconomic status (SES)-related variables in our study (maternal education, race/ethnicity, insurance status at delivery, and maternal birth outside the United States) did not alter our results. Concerns regarding confounding by SES may be lower in this population-based study relative to clinic-based samples. However, our study population, although comparable to its source population of California ([@c43]) with a high proportion of Hispanics and individuals on government-funded insurance relative to the general U.S. population, may have reduced generalizability to some other regions. We did not have information on maternal IQ, a predictor of child IQ, though we did adjust for maternal education. We also cannot rule out potential ID misclassification, given that ID was determined only according to available standardized test scores in diagnostic records; however, such records were reviewed by a trained clinician. We did not have the ability to examine the influence of certain pregnancy complications such as gestational diabetes or changes in body mass index, factors that may influence bioavailability of these compounds and may put an individual at higher risk for ASD; however, we did adjust for maternal weight at blood sample collection. It is likely that the influence of BFR exposure could vary by genetics; thus, additional consideration of how genetics influences the impact of these exposures is warranted. Finally, though we examined adjustment for exposure to PCBs, and this did not alter findings, future work should consider employing the emerging methodologies to handle exposure to mixtures of chemicals.

Conclusions {#s5}
===========

The primary analyses of this study did not support the hypothesis that prenatal PBDEs increase risk of ASD or ID. Results overall suggested a lack of an association to reductions in odds of ASD and ID with higher levels of BFRs, particularly for ASD in children born to mothers with levels of certain BDEs in the highest quartile relative to those with levels in the lowest quartile. However, findings from stratified analyses suggested the potential for effect modification by child sex, with the inverse associations for exposure to higher levels of prenatal PBDEs observed in boys. Associations in the opposite direction were suggested for girls, but we lacked precision in these estimates owing to smaller numbers. Given limited human studies on the developmental effects of exposure to these ubiquitous chemicals, continued investigation is needed. Future work with sufficient numbers of male and female cases should confirm whether associations seen here are replicated and investigate whether PBDEs are associated with developmental disorders, and ASD in particular, through sexually dimorphic pathways.
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